Steffen Klippel

1.6k citations

27 papers · 1.2k indexed · h-index 15

Co-authors: Paul G. Richardson Constantine S. Mitsiades Kenneth C. Anderson Douglas W. McMillin Jake Delmore Heike L. Pahl Nikhil C. Munshi Elisabeth Strunck
Topics: Multiple Myeloma Research and Treatments (14 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers)Acute Myeloid Leukemia Research (6 papers)
Cited by: Hematology Genetics Oncology
Journals: Nature Medicine Nature Genetics Blood
Partner nations: United States Germany Slovakia

In The Last Decade

Steffen Klippel

27 papers receiving 1.2k citations

Peers

Countries citing papers authored by Steffen Klippel

Since Specialization

Citations

This map shows the geographic impact of Steffen Klippel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Klippel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Klippel more than expected).

Fields of papers citing papers by Steffen Klippel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Klippel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Klippel. The network helps show where Steffen Klippel may publish in the future.

Co-authorship network of co-authors of Steffen Klippel

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Klippel. A scholar is included among the top collaborators of Steffen Klippel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Klippel. Steffen Klippel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents 2012 ·British Journal of Haematology ·Merav Leiba,Jana Jakubı́ková,Steffen Klippel,Constantine S. Mitsiades,Teru Hideshima,Yu‐Tzu Tai,Adi Leiba,Mark Pines,Paul G. Richardson,Arnon Nagler,Kenneth C. Anderson	28
2	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications 2011 ·Blood ·Jana Jakubı́ková,Sophia Adamia,Maria Kost‐Alimova,Steffen Klippel,David Cervi,John Daley,Dana Cholujová,Sun‐Young Kong,Merav Leiba,Simona Blotta,Melissa Ooi,Jake Delmore,Jacob P. Laubach,Paul G. Richardson,Ján Sedlák,Kenneth C. Anderson,Constantine S. Mitsiades	122
3	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma 2011 ·Haematologica ·Jana Jakubı́ková,David Cervi,Melissa Ooi,Kihyun Kım,Saifun Nahar,Steffen Klippel,Dana Cholujová,Merav Leiba,J F Daley,Jake Delmore,Joseph Negri,Simona Blotta,Douglas W. McMillin,Teru Hideshima,Paul G. Richardson,J Sedlák,K C Anderson,Constantine S. Mitsiades	63
4	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing 2011 ·Blood ·Niels W.C.J. van de Donk,Henk M. Lokhorst,Maarten E. Emmelot,Tineke Aarts‐Riemens,Douglas W. McMillin,Güllü Görgün,Steffen Klippel,Eugen Dhimolea,Jana Jakubı́ková,(unknown),(unknown),Jake Delmore,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades,Tuna Mutis	2
5	Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation 2011 ·PLoS ONE ·Douglas W. McMillin,Jake Delmore,Joseph Negri,Melissa Ooi,Steffen Klippel,Chandrasekhar V. Miduturu,Nathanael S. Gray,Paul G. Richardson,Kenneth C. Anderson,Andrew L. Kung,Constantine S. Mitsiades	24
6	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity 2010 ·Nature Medicine ·Douglas W. McMillin,Jake Delmore,Ellen Weisberg,Joseph Negri,(unknown),Steffen Klippel,Nicholas Mitsiades,Robert Schlossman,Nikhil C. Munshi,Andrew L. Kung,James D. Griffin,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades	236
7	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions. 2010 ·Blood ·Efstathios Kastritis,Jana Jakubı́ková,Jake Delmore,Steffen Klippel,Douglas W. McMillin,Melissa Ooi,Hannah M. Jacobs,Jacob P. Laubach,Paul G. Richardson,Kenneth C. Anderson,Andrew L. Kung,Constantine S. Mitsiades	1
8	Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib 2009 ·Seminars in Hematology ·Constantine S. Mitsiades,Teru Hideshima,Dharminder Chauhan,Douglas W. McMillin,Steffen Klippel,Jacob P. Laubach,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson	46
9	In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 2009 ·British Journal of Haematology ·Joseph Negri,Douglas W. McMillin,Jake Delmore,Nicholas Mitsiades,Patrick Hayden,Steffen Klippel,Teru Hideshima,Dharminder Chauhan,Nikhil C. Munshi,Carolyn A. Buser,John R. Pollard,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades	26
10	The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias. 2009 ·Blood ·Melissa Ooi,Robert O’Connor,Jana Jakubı́ková,Justine Meiller,Steffen Klippel,Jake Delmore,Efstathios Kastritis,Douglas W. McMillin,Martin Clynes,Paul G. Richardson,Constantine S. Mitsiades,Peter O’Gorman,Kenneth C. Anderson	1
11	The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies. 2009 ·Blood ·Jake Delmore,David Cervi,Douglas W. McMillin,Efstathios Kastritis,Jana Jakubı́ková,Melissa Ooi,Steffen Klippel,Joseph Negri,Leutz Buon,Jacob P. Laubach,Luca Rastelli,(unknown),(unknown),Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades	1
12	Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics 2008 ·Blood ·Melissa Ooi,Douglas W. McMillin,Joseph Negri,Jake Delmore,Steffen Klippel,Nicholas Mitsiades,Paul G. Richardson,Kenneth C. Anderson,Constantine S. Mitsiades	2
13	The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies 2007 ·Hematology/Oncology Clinics of North America ·Constantine S. Mitsiades,Douglas W. McMillin,Steffen Klippel,Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson	94
14	Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells 2006 ·Nature Genetics ·Ulrich Steidl,Frank Rosenbauer,Roel G.W. Verhaak,Xuesong Gu,Alexander K. Ebralidze,Hasan H. Otu,Steffen Klippel,Christian Steidl,Ingmar Bruns,Daniel B. Costa,Katharina Wagner,Manuel Aivado,Guido Kobbe,Peter J.M. Valk,Emmanuelle Passegué,Towia A. Libermann,Ruud Delwel,Daniel G. Tenen	132
15	Essential Role of Jun Family Transcription Factors in PU.1-Induced Leukemic Stem Cell Transformation. 2005 ·Blood ·Ulrich Steidl,Frank Rosenbauer,Roel G.W. Verhaak,Xuesong Gu,Hasan H. Otu,(unknown),Bronwyn M. Owens,Steffen Klippel,Katharina Wagner,Manuel Aivado,Emmanuelle Passegué,Towia A. Libermann,Ruud Delwel,Daniel G. Tenen	3
16	Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders 2004 ·Pathologie Biologie ·Steffen Klippel,Heike L. Pahl	8
17	PRV-1 mRNA expression discriminates two types of essential thrombocythemia 2004 ·Annals of Hematology ·Martin Grießhammer,Steffen Klippel,Elisabeth Strunck,S. Temerinac,(unknown),H. Heimpel,Heike L. Pahl	47
18	Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis 2003 ·Blood ·Steffen Klippel	63
19	Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera 2002 ·Blood ·Steffen Klippel,Elisabeth Strunck,Christian E. Busse,Dirk Behringer,Heike L. Pahl	47
20	Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera 2000 ·Blood ·S. Temerinac,Steffen Klippel,Elisabeth Strunck,(unknown),Michael Lübbert,W. Lange,Marc Azémar,Gerold Meinhardt,Hans‐Eckart Schaefer,Heike L. Pahl	164

About Steffen Klippel

Steffen Klippel is a scholar working on Hematology, Genetics and Oncology, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Myeloid Leukemia Research (6 papers). The work is most often cited by research in Hematology (611 citations), Genetics (326 citations) and Oncology (363 citations). Steffen Klippel has collaborated with scholars based in United States, Germany and Slovakia. Frequent co-authors include Paul G. Richardson, Constantine S. Mitsiades, Kenneth C. Anderson, Douglas W. McMillin, Jake Delmore, Heike L. Pahl, Nikhil C. Munshi, Elisabeth Strunck, Joseph Negri and Teru Hideshima. Their work appears in journals such as Nature Medicine, Nature Genetics and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact